MANNKIND CORP Contract Liability (Deferred Revenue)
MANNKIND CORP (MNKD) had Contract Liability (Deferred Revenue) of $11.09 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-05
- 2026-06-30: Contract with Customer, Liability, Current $11.09M.
- 2026-03-31: Contract with Customer, Liability, Current $11.53M.
- 2025-12-31: Contract with Customer, Liability, Current $15.33M.
- 2025-09-30: Contract with Customer, Liability, Current $10.12M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-06-30 | $11.09M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $11.53M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $15.33M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $10.12M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $10.95M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $11.76M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $12.41M 10-K · filed 2026-02-26 |
| 2024-09-30 | $6.52M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $7.42M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $7.60M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $9.09M 10-K · filed 2025-02-26 |
| 2023-09-30 | $3.67M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $3.49M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $2.32M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $1.73M 10-K · filed 2024-02-27 |
| 2022-09-30 | $1.79M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $1.67M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $1.31M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $827.00K 10-K · filed 2023-02-23 |
| 2021-09-30 | $14.02M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $20.13M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $25.88M 10-Q · filed 2021-05-12 |
| 2020-12-31 | $33.27M 10-K · filed 2022-02-24 |
| 2020-09-30 | $28.87M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $32.18M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $30.84M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $32.50M 10-K · filed 2021-02-25 |
| 2019-09-30 | $32.21M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $32.37M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $32.38M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $36.88M 10-K · filed 2020-02-25 |
| 2017-12-31 | $250.00K 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |